+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Type 1 Diabetes Drug Market Research Report by Form (Insulin Therapy and Oral Medication), End User, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • PDF Icon

    Report

  • 227 Pages
  • July 2022
  • Region: Global
  • 360iResearch™
  • ID: 4985893
UP TO OFF until Dec 31st 2022
The Global Type 1 Diabetes Drug Market size was estimated at USD 14.83 billion in 2021, USD 16.13 billion in 2022, and is projected to grow at a CAGR 8.95% to reach USD 24.81 billion by 2027.

Market Statistics:


The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Type 1 Diabetes Drug to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Form, the market was studied across Insulin Therapy and Oral Medication. The Insulin Therapy is further studied across Long-Acting Insulin, Premix Analogs, and Rapid Acting Insulin. The Oral Medication is further studied across Biguanides and Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors. The Biguanides is further studied across Metformine and Metformine Extended-Release. The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors is further studied across Canaglifozine, Dapagliflozine, Empagliflozine, and Ertugliflozine.
  • Based on End User, the market was studied across Drugstore and Hospital.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Type 1 Diabetes Drug market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Type 1 Diabetes Drug Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Type 1 Diabetes Drug Market, including Albireo, Astellas Pharma Inc., Astrazeneca PLC, B.braun Melsungen AG, Biocon Limited, Bristol Myers Squibb, C.H. Boehringer Sohn AG & Ko. KG, DiaVacs, Inc., Eli Lilly and Company, Glaxosmithkline PLC, Janssen Pharmaceuticals, Johnson & Johnson Services, Inc., Lupin Limited, Macrogenics, Inc., Merck & Co., Inc., Mylan N.V., Novartis International AG, Novo Nordisk A/s, Pfizer Inc., Piramal Healthcare Limited, Samsung Bioepis Co., Ltd., Sanofi S.A., Teva Pharmaceutical Industries Ltd., and XOMA Corp..

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Type 1 Diabetes Drug Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Type 1 Diabetes Drug Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Type 1 Diabetes Drug Market?
4. What is the competitive strategic window for opportunities in the Global Type 1 Diabetes Drug Market?
5. What are the technology trends and regulatory frameworks in the Global Type 1 Diabetes Drug Market?
6. What is the market share of the leading vendors in the Global Type 1 Diabetes Drug Market?
7. What modes and strategic moves are considered suitable for entering the Global Type 1 Diabetes Drug Market?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing Incidences of Type 1 Diabetes Globally
5.1.1.2. Increasing Healthcare Expenditure with Rising Disposable Income
5.1.1.3. Rising Patient Awareness on Type 1 Diabetes Treatment
5.1.2. Restraints
5.1.2.1. Patent Expiration of Drugs
5.1.3. Opportunities
5.1.3.1. Emerging Introduction of Novel Drugs to Treat Diabetes
5.1.3.2. Surge in Research and Development Activities for Type 1 Anti-Diabetic Drugs
5.1.4. Challenges
5.1.4.1. Strict Regulations for the Approval Drugs
5.2. Cumulative Impact of COVID-19
6. Type 1 Diabetes Drug Market, by Form
6.1. Introduction
6.2. Insulin Therapy
6.2.1. Long-Acting Insulin
6.2.2. Premix Analogs
6.2.3. Rapid Acting Insulin
6.3. Oral Medication
6.3.1. Biguanides
6.3.1.1. Metformine
6.3.1.2. Metformine Extended-Release
6.3.2. Sodium Glucose Cotransporter 2 (Sglt2) Inhibitors
6.3.2.1. Canaglifozine
6.3.2.2. Dapagliflozine
6.3.2.3. Empagliflozine
6.3.2.4. Ertugliflozine
7. Type 1 Diabetes Drug Market, by End-user
7.1. Introduction
7.2. Drugstore
7.3. Hospital
8. Americas Type 1 Diabetes Drug Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Type 1 Diabetes Drug Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
10. Europe, Middle East & Africa Type 1 Diabetes Drug Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom
11. Competitive Landscape
11.1. Fpnv Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, by Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion
12. Company Usability Profiles
12.1. Albireo
12.2. Astellas Pharma Inc.
12.3. Astrazeneca plc
12.4. B.Braun Melsungen Ag
12.5. Biocon Limited
12.6. Bristol Myers Squibb
12.7. C.H. Boehringer Sohn AG & Ko. Kg
12.8. Diavacs, Inc.
12.9. Eli Lilly and Company
12.10. GlaxoSmithKline plc
12.11. Janssen Pharmaceuticals
12.12. Johnson & Johnson Services, Inc.
12.13. Lupin Limited
12.14. Macrogenics, Inc.
12.15. Merck & Co., Inc.
12.16. Mylan N.V.
12.17. Novartis International Ag
12.18. Novo Nordisk A/S
12.19. Pfizer Inc.
12.20. Piramal Healthcare Limited
12.21. Samsung Bioepis Co., Ltd.
12.22. Sanofi S.A.
12.23. Teva Pharmaceutical Industries Ltd.
12.24. Xoma Corp.
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL TYPE 1 DIABETES DRUG MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2021 VS 2027 (USD BILLION)
FIGURE 3. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 4. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2021 VS 2027 (%)
FIGURE 5. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2027
FIGURE 7. GLOBAL TYPE 1 DIABETES DRUG MARKET DYNAMICS
FIGURE 8. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2021 VS 2027 (%)
FIGURE 9. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2021 VS 2027 (USD BILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2027
FIGURE 11. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2019-2027 (USD BILLION)
FIGURE 12. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 13. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING INSULIN, 2019-2027 (USD BILLION)
FIGURE 14. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING INSULIN, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 15. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PREMIX ANALOGS, 2019-2027 (USD BILLION)
FIGURE 16. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PREMIX ANALOGS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 17. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID ACTING INSULIN, 2019-2027 (USD BILLION)
FIGURE 18. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID ACTING INSULIN, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 19. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2019-2027 (USD BILLION)
FIGURE 20. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 21. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2019-2027 (USD BILLION)
FIGURE 22. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 23. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE, 2019-2027 (USD BILLION)
FIGURE 24. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 25. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE EXTENDED-RELEASE, 2019-2027 (USD BILLION)
FIGURE 26. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE EXTENDED-RELEASE, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 27. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2019-2027 (USD BILLION)
FIGURE 28. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 29. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CANAGLIFOZINE, 2019-2027 (USD BILLION)
FIGURE 30. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CANAGLIFOZINE, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 31. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DAPAGLIFLOZINE, 2019-2027 (USD BILLION)
FIGURE 32. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DAPAGLIFLOZINE, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 33. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY EMPAGLIFLOZINE, 2019-2027 (USD BILLION)
FIGURE 34. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY EMPAGLIFLOZINE, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 35. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ERTUGLIFLOZINE, 2019-2027 (USD BILLION)
FIGURE 36. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ERTUGLIFLOZINE, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 37. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2021 VS 2027 (%)
FIGURE 38. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2021 VS 2027 (USD BILLION)
FIGURE 39. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2027
FIGURE 40. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUGSTORE, 2019-2027 (USD BILLION)
FIGURE 41. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUGSTORE, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 42. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL, 2019-2027 (USD BILLION)
FIGURE 43. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 44. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 45. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 46. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD BILLION)
FIGURE 47. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2027
FIGURE 48. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 49. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 50. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 51. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 52. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 53. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 54. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 55. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY STATE, 2027
FIGURE 56. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 57. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 58. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD BILLION)
FIGURE 59. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2027
FIGURE 60. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 61. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 62. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 63. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 64. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 65. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 66. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 67. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 68. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 69. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 70. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 71. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 72. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 73. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD BILLION)
FIGURE 74. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2027
FIGURE 75. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 76. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 77. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 78. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 79. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 80. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 81. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 82. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 83. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 84. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 85. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 86. GLOBAL TYPE 1 DIABETES DRUG MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 87. GLOBAL TYPE 1 DIABETES DRUG MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 88. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL TYPE 1 DIABETES DRUG MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL TYPE 1 DIABETES DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 4. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2019-2027 (USD BILLION)
TABLE 5. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2019-2027 (USD BILLION)
TABLE 6. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, BY REGION, 2019-2027 (USD BILLION)
TABLE 7. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 8. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, BY STATE, 2019-2027 (USD BILLION)
TABLE 9. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 10. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 11. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING INSULIN, BY REGION, 2019-2027 (USD BILLION)
TABLE 12. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING INSULIN, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 13. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING INSULIN, BY STATE, 2019-2027 (USD BILLION)
TABLE 14. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING INSULIN, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 15. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING INSULIN, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 16. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PREMIX ANALOGS, BY REGION, 2019-2027 (USD BILLION)
TABLE 17. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY PREMIX ANALOGS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 18. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY PREMIX ANALOGS, BY STATE, 2019-2027 (USD BILLION)
TABLE 19. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY PREMIX ANALOGS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 20. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PREMIX ANALOGS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 21. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID ACTING INSULIN, BY REGION, 2019-2027 (USD BILLION)
TABLE 22. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID ACTING INSULIN, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 23. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID ACTING INSULIN, BY STATE, 2019-2027 (USD BILLION)
TABLE 24. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID ACTING INSULIN, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 25. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID ACTING INSULIN, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 26. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, BY REGION, 2019-2027 (USD BILLION)
TABLE 27. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 28. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, BY STATE, 2019-2027 (USD BILLION)
TABLE 29. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 30. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 31. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, BY REGION, 2019-2027 (USD BILLION)
TABLE 32. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 33. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, BY STATE, 2019-2027 (USD BILLION)
TABLE 34. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 35. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 36. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE, BY REGION, 2019-2027 (USD BILLION)
TABLE 37. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 38. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE, BY STATE, 2019-2027 (USD BILLION)
TABLE 39. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 40. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 41. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE EXTENDED-RELEASE, BY REGION, 2019-2027 (USD BILLION)
TABLE 42. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE EXTENDED-RELEASE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 43. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE EXTENDED-RELEASE, BY STATE, 2019-2027 (USD BILLION)
TABLE 44. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE EXTENDED-RELEASE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 45. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE EXTENDED-RELEASE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 46. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, BY REGION, 2019-2027 (USD BILLION)
TABLE 47. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 48. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, BY STATE, 2019-2027 (USD BILLION)
TABLE 49. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 50. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 51. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CANAGLIFOZINE, BY REGION, 2019-2027 (USD BILLION)
TABLE 52. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY CANAGLIFOZINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 53. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY CANAGLIFOZINE, BY STATE, 2019-2027 (USD BILLION)
TABLE 54. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY CANAGLIFOZINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 55. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY CANAGLIFOZINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 56. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DAPAGLIFLOZINE, BY REGION, 2019-2027 (USD BILLION)
TABLE 57. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY DAPAGLIFLOZINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 58. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY DAPAGLIFLOZINE, BY STATE, 2019-2027 (USD BILLION)
TABLE 59. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY DAPAGLIFLOZINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 60. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DAPAGLIFLOZINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 61. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY EMPAGLIFLOZINE, BY REGION, 2019-2027 (USD BILLION)
TABLE 62. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY EMPAGLIFLOZINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 63. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY EMPAGLIFLOZINE, BY STATE, 2019-2027 (USD BILLION)
TABLE 64. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY EMPAGLIFLOZINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 65. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY EMPAGLIFLOZINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 66. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ERTUGLIFLOZINE, BY REGION, 2019-2027 (USD BILLION)
TABLE 67. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY ERTUGLIFLOZINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 68. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY ERTUGLIFLOZINE, BY STATE, 2019-2027 (USD BILLION)
TABLE 69. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY ERTUGLIFLOZINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 70. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY ERTUGLIFLOZINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 71. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2019-2027 (USD BILLION)
TABLE 72. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUGSTORE, BY REGION, 2019-2027 (USD BILLION)
TABLE 73. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUGSTORE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 74. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUGSTORE, BY STATE, 2019-2027 (USD BILLION)
TABLE 75. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUGSTORE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUGSTORE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 77. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL, BY REGION, 2019-2027 (USD BILLION)
TABLE 78. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 79. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL, BY STATE, 2019-2027 (USD BILLION)
TABLE 80. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 82. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 83. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 84. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2019-2027 (USD BILLION)
TABLE 85. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2019-2027 (USD BILLION)
TABLE 86. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 87. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2019-2027 (USD BILLION)
TABLE 88. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2019-2027 (USD BILLION)
TABLE 89. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 90. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2019-2027 (USD BILLION)
TABLE 91. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2019-2027 (USD BILLION)
TABLE 92. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 93. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2019-2027 (USD BILLION)
TABLE 94. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2019-2027 (USD BILLION)
TABLE 95. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 96. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2019-2027 (USD BILLION)
TABLE 97. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2019-2027 (USD BILLION)
TABLE 98. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 99. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY STATE, 2019-2027 (USD BILLION)
TABLE 100. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2019-2027 (USD BILLION)
TABLE 101. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2019-2027 (USD BILLION)
TABLE 102. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 103. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 104. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2019-2027 (USD BILLION)
TABLE 105. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2019-2027 (USD BILLION)
TABLE 106. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 107. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2019-2027 (USD BILLION)
TABLE 108. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2019-2027 (USD BILLION)
TABLE 109. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 110. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2019-2027 (USD BILLION)
TABLE 111. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2019-2027 (USD BILLION)
TABLE 112. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 113. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2019-2027 (USD BILLION)
TABLE 114. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2019-2027 (USD BILLION)
TABLE 115. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 116. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2019-2027 (USD BILLION)
TABLE 117. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2019-2027 (USD BILLION)
TABLE 118. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 119. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2019-2027 (USD BILLION)
TABLE 120. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2019-2027 (USD BILLION)
TABLE 121. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 122. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2019-2027 (USD BILLION)
TABLE 123. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2019-2027 (USD BILLION)
TABLE 124. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 125. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2019-2027 (USD BILLION)
TABLE 126. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2019-2027 (USD BILLION)
TABLE 127. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 128. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2019-2027 (USD BILLION)
TABLE 129. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2019-2027 (USD BILLION)
TABLE 130. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 131. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2019-2027 (USD BILLION)
TABLE 132. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2019-2027 (USD BILLION)
TABLE 133. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 134. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2019-2027 (USD BILLION)
TABLE 135. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2019-2027 (USD BILLION)
TABLE 136. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 137. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2019-2027 (USD BILLION)
TABLE 138. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2019-2027 (USD BILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2019-2027 (USD BILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2019-2027 (USD BILLION)
TABLE 143. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 144. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2019-2027 (USD BILLION)
TABLE 145. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2019-2027 (USD BILLION)
TABLE 146. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 147. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2019-2027 (USD BILLION)
TABLE 148. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2019-2027 (USD BILLION)
TABLE 149. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 150. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2019-2027 (USD BILLION)
TABLE 151. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2019-2027 (USD BILLION)
TABLE 152. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 153. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2019-2027 (USD BILLION)
TABLE 154. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2019-2027 (USD BILLION)
TABLE 155. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 156. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2019-2027 (USD BILLION)
TABLE 157. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2019-2027 (USD BILLION)
TABLE 158. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 159. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2019-2027 (USD BILLION)
TABLE 160. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2019-2027 (USD BILLION)
TABLE 161. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 162. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2019-2027 (USD BILLION)
TABLE 163. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2019-2027 (USD BILLION)
TABLE 164. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 165. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2019-2027 (USD BILLION)
TABLE 166. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2019-2027 (USD BILLION)
TABLE 167. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 168. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2019-2027 (USD BILLION)
TABLE 169. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2019-2027 (USD BILLION)
TABLE 170. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 171. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2019-2027 (USD BILLION)
TABLE 172. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2019-2027 (USD BILLION)
TABLE 173. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 174. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2019-2027 (USD BILLION)
TABLE 175. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2019-2027 (USD BILLION)
TABLE 176. GLOBAL TYPE 1 DIABETES DRUG MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 177. GLOBAL TYPE 1 DIABETES DRUG MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 178. GLOBAL TYPE 1 DIABETES DRUG MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 179. GLOBAL TYPE 1 DIABETES DRUG MARKET RANKING
TABLE 180. GLOBAL TYPE 1 DIABETES DRUG MARKET SHARE, BY KEY PLAYER, 2021
TABLE 181. GLOBAL TYPE 1 DIABETES DRUG MARKET MERGER & ACQUISITION
TABLE 182. GLOBAL TYPE 1 DIABETES DRUG MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 183. GLOBAL TYPE 1 DIABETES DRUG MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 184. GLOBAL TYPE 1 DIABETES DRUG MARKET INVESTMENT & FUNDING
TABLE 185. GLOBAL TYPE 1 DIABETES DRUG MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 186. GLOBAL TYPE 1 DIABETES DRUG MARKET: LICENSE & PRICING

Companies Mentioned

  • Albireo
  • Astellas Pharma Inc.
  • Astrazeneca PLC
  • B.braun Melsungen AG
  • Biocon Limited
  • Bristol Myers Squibb
  • C.H. Boehringer Sohn AG & Ko. KG
  • DiaVacs, Inc.
  • Eli Lilly and Company
  • Glaxosmithkline PLC
  • Janssen Pharmaceuticals
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Macrogenics, Inc.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis International AG
  • Novo Nordisk A/s
  • Pfizer Inc.
  • Piramal Healthcare Limited
  • Samsung Bioepis Co., Ltd.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • XOMA Corp.

Methodology

Loading
LOADING...